glp 1 drugs and breast cancer GLP-1 Receptor Agonists Show a Striking Signal in Outcomes, but Big Questions Remain GLP-1 Receptor Agonists in Breast
Description
We included costs of lost earnings due to absenteeism (acute and chronic), workforce dropout due to CVD or ESKD, and loss of future earnings from premature mortality (death before retirement age, which was set at 67 years)
"This solution is really focused towards clients that aren't covering it today, and what it allows us to do is one, to bring it on at a reduced price for the plan sponsor, but also capping out the members' cost at $200," per month said Harold Carter, Evernorth senior vice president of pharmacy relations
[PubMed ID: 29364584]
doi: 10.1038/s41598-024-57724-5
